AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...

Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...

Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...

AstraZeneca’s Chief Medical (TASE:BLWV) Officer, Cristian Massacesi, highlighted the trial’s role in demonstrating the efficacy of Imfinzi in resectable gastric and GEJ cancers, reinforcing the ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage ...

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...